Osmotica Pharmaceuticals plc to Discuss Third Quarter 2018 Financial Results on November 8, 2018
||Thursday, November 8, 2018
||4:30 p.m. EST
|Toll free (U.S.)
|Webcast (live and replay)||www.osmotica.com under the “Investor & News” section|
A replay of the conference call will be available for one week after the call's completion by dialing (855) 859-2056 (US) or (404) 537-3406 (International) and entering conference call ID 1018838. The webcast will be archived for 30 days at the aforementioned URL.
Osmotica has a late-stage development pipeline highlighted by two NDA candidates in Phase III clinical trials: arbaclofen extended-release tablets for muscle spasticity in multiple sclerosis patients and RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for the treatment of blepharoptosis, or droopy eyelid.
Osmotica has operations in
Investor and Media Relations for
In-Site Communications, Inc.
Source: Osmotica Holdings US LLC